3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Recruiting
2
Active not recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
NET
2
Endocrine
2
Sarcoma
1
Lymphoid
1
Gastrointestinal
1
CNS
1
Conditions
Neuroendocrine Tumors
2
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Central Nervous System Neoplasms
1
Interventions
Specimen Handling
480
pembrolizumab
455
Magnetic Resonance Spectroscopy
420
Carboplatin
327
Cyclophosphamide
314
Cisplatin
271
Biopsy
271
Radiotherapy
244
Paclitaxel
229
Gemcitabine
227
Bevacizumab
213
Nivolumab
188
fludarabine
185
venetoclax
174
Drug Therapy
170
Blood Specimen Collection
158
Dexamethasone
157
Oxaliplatin
154
Injections
152
Capecitabine
151
Fluorouracil
144
Docetaxel
144
Radiosurgery
137
Standard of Care
135
Rituximab
125
Pemetrexed
117
durvalumab
115
Leucovorin
109
atezolizumab
107
Radiation
106
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
amino-acid, glucose, and electrolyte solution
×
1 year
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled
NCT06878664
2025-09-02
RIALTO
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Recruiting
166 enrolled